Arcellx appoints andrew galligan and kristin myers to its board of directors

Redwood city, calif.--(business wire)--arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of andrew galligan and kristin myers to its board of directors. mr. galligan is a proven financial executive who brings over three decades of strategic leadership experience to the arcellx board. ms. myers, a highly experienced healthcare.
ACLX Ratings Summary
ACLX Quant Ranking